Connect Biopharma (NASDAQ:CNTB) Given “Buy” Rating at BTIG Research

BTIG Research restated their buy rating on shares of Connect Biopharma (NASDAQ:CNTB) in a research report released on Tuesday,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

CNTB has been the subject of a number of other reports. Wall Street Zen upgraded shares of Connect Biopharma to a “hold” rating in a research report on Saturday, December 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Connect Biopharma in a research note on Wednesday, January 21st. Finally, Lake Street Capital began coverage on shares of Connect Biopharma in a report on Monday, December 1st. They issued a “buy” rating and a $9.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Connect Biopharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.67.

Connect Biopharma Stock Down 9.7%

CNTB stock opened at $2.62 on Tuesday. The stock has a 50-day simple moving average of $2.69 and a two-hundred day simple moving average of $2.31. Connect Biopharma has a twelve month low of $0.51 and a twelve month high of $3.82. The firm has a market capitalization of $146.46 million, a PE ratio of -3.59 and a beta of -0.20. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new stake in Connect Biopharma in the fourth quarter valued at approximately $2,235,000. Knott David M Jr purchased a new position in Connect Biopharma in the 4th quarter worth approximately $564,000. Richmond Brothers Inc. bought a new position in shares of Connect Biopharma in the 4th quarter worth $489,000. Marshall Wace LLP increased its holdings in shares of Connect Biopharma by 121.2% in the 4th quarter. Marshall Wace LLP now owns 128,368 shares of the company’s stock worth $362,000 after buying an additional 70,337 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Connect Biopharma during the 4th quarter valued at $232,000. 58.72% of the stock is currently owned by institutional investors.

More Connect Biopharma News

Here are the key news stories impacting Connect Biopharma this week:

• Positive Sentiment: Phase 3 atopic dermatitis results touted “best‑in‑class” potential with rapid, durable efficacy through 52 weeks — strong efficacy messaging likely supported the prior rally. Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
• Positive Sentiment: Positive topline Phase 1 IV rademikibart data in asthma/COPD showed rapid FEV1 improvements (many ≥200 mL within 15 minutes), supporting additional indications and near-term data catalysts. Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
• Positive Sentiment: BTIG Research reaffirmed a “buy” rating with a $10 price target, signaling strong analyst confidence and a sizable upside vs. current levels. Benzinga
• Neutral Sentiment: Company filed its 2025 full‑year results and provided a business update: Phase 2 Seabreeze STAT trials in acute asthma/COPD are recruiting with topline expected mid‑2026 — offers additional near‑term catalysts but no revenue guidance. Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
• Neutral Sentiment: Company management and analysts discussed the Phase 3 AD data in a transcript/earnings-style update — useful for investors parsing durability and safety details but not a standalone catalyst. Connect Biopharma Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript
• Negative Sentiment: Private placement: company agreed to sell 6.13M shares at $3.25 for gross proceeds ~ $20.2M — while it extends cash runway into H2 2027, the financing raises dilution concerns that likely pressured the stock after the initial clinical‑data pop. Connect Biopharma Announces $20.2 Million Private Placement Financing
• Negative Sentiment: Market commentary and news pieces highlight volatility and the post‑data pullback; some writeups explicitly explore why the stock fell after the initial surge (profit‑taking + financing concerns). Why Connect Biopharma Holdings Limited’s (CNTB) Stock Is Down 16.96%

About Connect Biopharma

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.